-
1
-
-
0037145863
-
CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
-
Steinhubl SR, Berger PB, Mann JT 3rd, et al.; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
-
(2002)
J Am Med Assoc
, vol.288
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann III, J.T.3
-
2
-
-
0035908781
-
Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
-
Mehta SR, Yusuf S, Peters RJ, et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
-
(2001)
Lancet
, vol.358
, pp. 527-533
-
-
Mehta, S.R.1
Yusuf, S.2
Peters, R.J.3
-
3
-
-
77953911457
-
Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate
-
Bonello L, Tantry US, Marcucci R, et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 919-933
-
-
Bonello, L.1
Tantry, U.S.2
Marcucci, R.3
-
4
-
-
78349244351
-
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis
-
Siller-Matula JM, Jilma B, Schrör K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624-2641.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 2624-2641
-
-
Siller-Matula, J.M.1
Jilma, B.2
Schrör, K.3
-
5
-
-
80052953534
-
Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention
-
Rideg O, Komócsi A, Magyarlaki T, et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 2011; 2011; 12: 1269-1280.
-
(2011)
Pharmacogenomics
, vol.2011
, Issue.12
, pp. 1269-1280
-
-
Rideg, O.1
Komócsi, A.2
Magyarlaki, T.3
-
6
-
-
37849002889
-
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
-
Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
-
(2008)
Eur Heart J
, vol.29
, pp. 21-30
-
-
Wallentin, L.1
Varenhorst, C.2
James, S.3
-
7
-
-
33646732608
-
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
-
Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
-
(2006)
Eur Heart J
, vol.27
, pp. 1166-1173
-
-
Jernberg, T.1
Payne, C.D.2
Winters, K.J.3
-
8
-
-
37349111065
-
PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
-
Wiviott SD, Trenk D, Frelinger AL, et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
-
(2007)
Circulation
, vol.116
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
-
9
-
-
38349168418
-
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
-
Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222.
-
(2008)
Thromb Haemost
, vol.99
, pp. 215-222
-
-
Jakubowski, J.A.1
Payne, C.D.2
Li, Y.G.3
-
10
-
-
79960603731
-
High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes
-
Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467-473.
-
(2011)
J Am Coll Cardiol
, vol.58
, pp. 467-473
-
-
Bonello, L.1
Pansieri, M.2
Mancini, J.3
-
11
-
-
77955603691
-
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window
-
Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 5: 317-318.
-
(2010)
J Am Coll Cardiol
, vol.5
, pp. 317-318
-
-
Sibbing, D.1
Steinhubl, S.R.2
Schulz, S.3
-
12
-
-
33750479499
-
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
-
Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 1742-1750
-
-
Hochholzer, W.1
Trenk, D.2
Bestehorn, H.P.3
-
13
-
-
67651173161
-
TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
-
Michelson AD, Frelinger AL 3rd, Braunwald E, et al; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
-
(2009)
Eur Heart J
, vol.30
, pp. 1753-1763
-
-
Michelson, A.D.1
Frelinger III, A.L.2
Braunwald, E.3
-
14
-
-
79952149001
-
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
-
Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 201; 32: 838-846.
-
Eur Heart J
, vol.201
, Issue.32
, pp. 838-846
-
-
Angiolillo, D.J.1
Badimon, J.J.2
Saucedo, J.F.3
-
15
-
-
0034068625
-
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
-
Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-1446.
-
(2000)
Br J Pharmacol
, vol.129
, pp. 1439-1446
-
-
Sugidachi, A.1
Asai, F.2
Ogawa, T.3
-
16
-
-
11844256436
-
Variability in platelet responsiveness to clopidogrel among 544 individuals
-
Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
-
(2005)
J Am Coll Cardiol
, vol.45
, pp. 246-251
-
-
Serebruany, V.L.1
Steinhubl, S.R.2
Berger, P.B.3
-
17
-
-
77958008430
-
Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition
-
Aradi D, Magyarlaki T, Tokés-Füzesi M, et al. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Platelets 2010; 21: 563-570.
-
(2010)
Platelets
, vol.21
, pp. 563-570
-
-
Aradi, D.1
Magyarlaki, T.2
Tokés-Füzesi, M.3
-
18
-
-
56849130022
-
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
-
Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-1977.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 1968-1977
-
-
Erlinge, D.1
Varenhorst, C.2
Braun, O.O.3
-
19
-
-
77958105401
-
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis
-
Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
-
(2010)
Lancet
, vol.376
, pp. 1312-1319
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
20
-
-
79961114506
-
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44
-
Frelinger AL 3rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
-
(2011)
Thromb Haemost
, vol.106
, pp. 219-226
-
-
Frelinger III, A.L.1
Michelson, A.D.2
Wiviott, S.D.3
-
21
-
-
70249139788
-
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
-
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
-
(2009)
Lancet
, vol.374
, pp. 989-997
-
-
O'Donoghue, M.L.1
Braunwald, E.2
Antman, E.M.3
-
22
-
-
77952591958
-
Impact of cytochrome P450 2C19 loss-offunction polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
-
Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-offunction polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2427-2434
-
-
Hochholzer, W.1
Trenk, D.2
Fromm, M.F.3
|